MedTrace Logo

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

NCT04740190 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2025-06-11

No results posted yet for this study

Summary

In view of the strong biological rationale of employing PARP inhibition in high grade glioma, the current study purposes testing of talazoparib in a biomarker-enriched group of glioma. Carboplatin will be added to sensitize the tumor to PARP inhibition, and low dose radiation therapy will be applied to increase talazoparib drug penetration through blood-brain barrier. The goal is to estimate the effect size of such combinational treatment approach in recurrent high-grade glioma with DNA damage repair deficiency (dDDR)

Conditions

  • Recurrent Glioma
  • Recurrent Glioblastoma
  • Poly ADP Ribose Polymerase (PARP) Inhibitor
  • PTEN Gene Inactivation
  • IDH Mutation

Interventions

DRUG

Talazoparib

low dose whole brain radiation, followed by combination talazoparib and carboplatin

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Aya Helali, MD, PhD · Department of Clinical Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2023-12-14
Completion
2023-12-14
FDA Drug
Yes

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04740190 on ClinicalTrials.gov